BioLight’s New Investment in Tarsius Pharma Ltd. that develops a novel platform for the treatment of blinding ocular diseases

Tel Aviv (October 6, 2019) – BioLight is pleased to announce that on October 3, 2019, it has signed a binding Simple Agreement for Future Equity (SAFE), together with other investors, for investment in Tarsius Pharma Ltd. (the “Agreement” and “Tarsius”), a private Israeli company developing a novel platform for the treatment of blinding ocular diseases.

 

Link to the complete article

Link to Newsroom

Comments are closed.